参考文献
［1］ 中国心血管健康与疾病报告编写组. 《中国心血管健康与疾病报告2021》概要［J］. 中国循环杂志, 2022, 37(6): 553‑578. DOI: 10.3969/j.issn.1000‑3614.2022.06.001.
［2］ Yock PG, Linker DT, Angelsen BA. Two‑dimensional intravascular ultrasound: technical development and initial clinical experience［J］. J Am Soc Echocardiogr, 1989,2(4):296‑304. DOI: 10.1016/s0894‑7317(89)80090‑2.
［3］ Hong SJ, Kim BK, Shin DH, et al. Effect of intravascular ultrasound‑guided vs angiography‑guided everolimus‑eluting stent implantation: the IVUS‑XPL randomized clinical trial［J］. JAMA, 2015,314(20):2155‑2163. DOI: 10.1001/jama.2015.15454.
［4］ Hong SJ, Mintz GS, Ahn CM, et al. Effect of intravascular ultrasound‑guided drug‑eluting stent implantation: 5‑year follow‑up of the ivus‑xpl randomized trial［J］. JACC Cardiovasc Interv, 2020,13(1):62‑71. DOI: 10.1016/j.jcin.2019.09.033.
［5］ Kim BK, Shin DH, Hong MK, et al. Clinical impact of intravascular ultrasound‑guided chronic total occlusion intervention with zotarolimus‑eluting versus biolimus‑eluting stent implantation: randomized study［J］. Circ Cardiovasc Interv, 2015,8(7):e002592. DOI: 10.1161/CIRCINTERVENTIONS.115.002592.
［6］ Zhang J, Gao X, Kan J, et al. Intravascular ultrasound versus angiography‑guided drug‑eluting stent implantation: the ULTIMATE trial［J］. J Am Coll Cardiol, 2018,72(24):3126‑3137. DOI: 10.1016/j.jacc.2018.09.013.
［7］ Gao XF, Ge Z, Kong XQ, et al. 3‑year outcomes of the ULTIMATE trial comparing intravascular ultrasound versus angiography‑guided drug‑eluting stent implantation［J］. JACC Cardiovasc Interv, 2021,14(3):247‑257. DOI: 10.1016/j.jcin.2020.10.001.
［8］ Jang IK, Bouma BE, Kang DH, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound［J］. J Am Coll Cardiol, 2002,39(4):604‑609. DOI: 10.1016/s0735‑1097(01)01799‑5.
［9］ Wijns W, Shite J, Jones MR, et al. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision‑making: ILUMIEN I study［J］. Eur Heart J, 2015,36(47):3346‑3355. DOI: 10.1093/eurheartj/ehv367.
［10］ Ali ZA, Maehara A, Généreux P, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial［J］. Lancet, 2016,388(10060):2618‑2628. DOI: 10.1016/S0140‑6736(16)31922‑5.
［11］ Jones DA, Rathod KS, Koganti S, et al. Angiography alone versus angiography plus optical coherence tomography to guide percutaneous coronary intervention: outcomes from the pan‑London PCI cohort［J］. JACC Cardiovasc Interv, 2018,11(14):1313‑1321. DOI: 10.1016/j.jcin.2018.01.274.
［12］ Lee SY, Kim JS, Yoon HJ, et al. Early strut coverage in patients receiving drug‑eluting stents and its implications for dual antiplatelet therapy: a randomized trial［J］. JACC Cardiovasc Imaging, 2018,11(12):1810‑1819. DOI: 10.1016/j.jcmg.2017.12.014.
［13］ Chamié D, Costa JR Jr, Damiani LP, et al. Optical coherence tomography versus intravascular ultrasound and angiography to guide percutaneous coronary interventions: the isight randomized trial［J］. Circ Cardiovasc Interv, 2021,14(3):e009452. DOI: 10.1161/CIRCINTERVENTIONS.120.009452.
［14］ Ali Z, Landmesser U, Karimi Galougahi K, et al. Optical coherence tomography‑guided coronary stent implantation compared to angiography: a multicentre randomised trial in PCI ‑design and rationale of ILUMIEN IV: OPTIMAL PCI［J］. EuroIntervention, 2021,16(13):1092‑1099. DOI: 10.4244/EIJ‑D‑20‑00501.
［15］ Holm NR, Andreasen LN, Walsh S, et al. Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER)［J］. Am Heart J, 2018,205:97‑109. DOI: 10.1016/j.ahj.2018.08.003.
［16］ Räber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions［J］. Eur Heart J, 2018,39(35):3281‑3300. DOI: 10.1093/eurheartj/ehy285.
［17］ Lawton JS, Tamis‑Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines［J］. Circulation, 2022,145(3):e4‑e17. DOI: 10.1161/CIR.0000000000001039.
［18］ Amabile N, Rangé G, Souteyrand G, et al. Optical coherence tomography to guide percutaneous coronary intervention of the left main coronary artery: the LEMON study［J］. EuroIntervention, 2021,17(2):e124‑e131. DOI: 10.4244/EIJ‑D‑20‑01121.
［19］ Cortese B, de la Torre Hernandez JM, Lanocha M, et al. Optical coherence tomography, intravascular ultrasound or angiography guidance for distal left main coronary stenting. The ROCK cohort II study［J］. Catheter Cardiovasc Interv, 2022,99(3):664‑673. DOI: 10.1002/ccd.29959.
［20］ Zhang M, Matsumura M, Usui E, et al. Intravascular ultrasound‑derived calcium score to predict stent expansion in severely calcified lesions［J］. Circ Cardiovasc Interv, 2021,14(10):e010296. DOI: 10.1161/CIRCINTERVENTIONS.120.010296.
［21］ Fujino A, Mintz GS, Matsumura M, et al. A new optical coherence tomography‑based calcium scoring system to predict stent underexpansion［J］. EuroIntervention, 2018,13(18):e2182‑e2189. DOI: 10.4244/EIJ‑D‑17‑00962.
［22］ Kurogi K, Ishii M, Ikebe S, et al. Optical coherence tomography‑versus intravascular ultrasound‑guided stent expansion in calcified lesions［J］. Cardiovasc Interv Ther, 2022,37(2):312‑323. DOI: 10.1007/s12928‑021‑00790‑7.
［23］ Galassi AR, Sumitsuji S, Boukhris M, et al. Utility of intravascular ultrasound in percutaneous revascularization of chronic total occlusions: an overview［J］. JACC Cardiovasc Interv, 2016,9(19):1979‑1991. DOI: 10.1016/j.jcin.2016.06.057.
［24］ Tian NL, Gami SK, Ye F, et al. Angiographic and clinical comparisons of intravascular ultrasound‑versus angiography‑guided drug‑eluting stent implantation for patients with chronic total occlusion lesions: two‑year results from a randomised AIR‑CTO study［J］. EuroIntervention, 2015,10(12):1409‑1417. DOI: 10.4244/EIJV10I12A245.
［25］ Jia H, Abtahian F, Aguirre AD, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography［J］. J Am Coll Cardiol, 2013,62(19):1748‑1758. DOI: 10.1016/j.jacc.2013.05.071.
［26］ Jia H, Dai J, Hou J, et al. Effective anti‑thrombotic therapy without stenting: intravascular optical coherence tomography‑based management in plaque erosion (the EROSION study)［J］. Eur Heart J, 2017,38(11):792‑800. DOI: 10.1093/eurheartj/ehw381.
［27］ Jia H, Dai J, He L, et al. EROSION III: a multicenter RCT of OCT‑guided reperfusion in STEMI with early infarct artery patency［J］. JACC Cardiovasc Interv, 2022,15(8):846‑856. DOI: 10.1016/j.jcin.2022.01.298.
［28］ Croce K, Wollmuth J, Mathew R, 等. LIGHTLAB研究：OCT影响PCI决策制定［R/OL］. （2020‑06‑30）［2022‑10‑18］. http://www.menzhen.org/wechat/MeetingVideoInfo?mmid=1006231632342650&id=1006301917220680.
［29］ Neumann FJ, Sousa‑Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization［J］. Eur Heart J, 2019,40(2):87‑165. DOI: 10.1093/eurheartj/ehy394.
［30］ Koo BK, Hu X, Kang J, et al. Fractional flow reserve or intravascular ultrasonography to guide PCI［J］. N Engl J Med, 2022,387(9):779‑789. DOI: 10.1056/NEJMoa2201546.
［31］ Burzotta F, Leone AM, Aurigemma C, et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis: a single‑center trial［J］. JACC Cardiovasc Interv, 2020,13(1):49‑58. DOI: 10.1016/j.jcin.2019.09.034.
［32］ Yu W, Huang J, Jia D, et al. Diagnostic accuracy of intracoronary optical coherence tomography‑derived fractional flow reserve for assessment of coronary stenosis severity［J］. EuroIntervention, 2019,15(2):189‑197. DOI: 10.4244/EIJ‑D‑19‑00182.
［33］ Stone GW, Maehara A, Lansky AJ, et al. A prospective natural‑history study of coronary atherosclerosis［J］. N Engl J Med, 2011,364(3):226‑235. DOI: 10.1056/NEJMoa1002358.
［34］ Erlinge D, Maehara A, Ben‑Yehuda O, et al. Identification of vulnerable plaques and patients by intracoronary near‑infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study［J］. Lancet, 2021,397(10278):985‑995. DOI: 10.1016/S0140‑6736(21)00249‑X.
［35］ Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study［J］. Eur Heart J, 2020,41(3):383‑391. DOI: 10.1093/eurheartj/ehz520.
［36］ Kedhi E, Berta B, Roleder T, et al. Thin‑cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT‑FFR trial［J］. Eur Heart J, 2021,42(45):4671‑4679. DOI: 10.1093/eurheartj/ehab433.
［37］ Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin‑treated patients following myocardial infarction［J］. JACC Cardiovasc Imaging, 2022,15(7):1308‑1321. DOI: 10.1016/j.jcmg.2022.03.002.
［38］ Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high‑intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN‑AMI randomized clinical trial［J］. JAMA, 2022,327(18):1771‑1781. DOI: 10.1001/jama.2022.5218.
［39］ 中华医学会心血管病学分会. 冠状动脉生物可吸收支架临床应用中国专家共识［J］. 中华心血管病杂志, 2020, 48 (5): 350‑358. DOI: 10.3760/cma.j.cn112148‑20200317‑00224.
［40］ Li L, Zhao L, Wang J, et al. Optical coherence tomography‑guided drug coated balloon in non‑small de novo coronary artery lesions: a prospective clinical research［J］. Am J Transl Res, 2021,13(10):11617‑11624.
［41］ Yerasi C, Case BC, Forrestal BJ, et al. Drug‑coated balloon for de novo coronary artery disease: JACC state‑of‑the‑art review［J］. J Am Coll Cardiol, 2020,75(9):1061‑1073. DOI: 10.1016/j.jacc.2019.12.046.
